Bartter's and Gitelman's syndromes: A confirm in humans of the utility of Rho kinase inhibition for cardiovascular protection [2]

Journal of Hypertension

Volumn 23, Issue 6, 2005, Pages 1273-1275

  Calò, Lorenzo A ^a   Pagnin, Elisa ^a   Sartori, Michelangelo ^a   Semplicini, Andrea ^a   Pessina, Achille C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; G PROTEIN COUPLED RECEPTOR; RHO KINASE;

BARTTER SYNDROME; ENZYME INHIBITION; GITELMAN SYNDROME; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; LETTER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE CONTRACTION;

EID: 20844441810     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000170394.99697.b3     Document Type: Letter

References (25)

1. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993; 361:315-325.
2. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G-proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83:1325-1358.
3. Sward K, Mita M, Wilson DP, Deng JT, Susnjar M, Walsh MP. The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction. Curr Hypertens Rep 2003; 5:66-72.
4. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001; 38:1307-1310.
5. Chitaley K, Weber D, Webb RC. RhoA/Rho-kinase, vascular changes and hypertension. Curr Hypertens Rep 2001; 3:139-144.
6. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, et al. Long-term inhibition of Rho-Kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Effect on endothelial NAD(P)H oxidase system. Circ Res 2003; 93:767-775.
7. Yamakawa T, Tanaka S, Numaguchi K, Yamakawa Y, Motley ED, Ichihara S, et al. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 2000; 35:313-318.
8. Kataoka C, Egashira K, Inoue S, Takemoto M, Ni W, Koyanagi M, et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002; 39:245-250.
9. Takeda K, Ichiki T, Tokunou T, Iino N, Fujii S, Kitabatake A, et al. Critical role of Rho-kinase and MEK-ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 2001; 21:868-873.
10. Eto Y, Shimokawa H, Hiroki J, Morishige K, Kandabashi T, Matsumoto Y, et al. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol 2000; 278:H1744-H1750.
11. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3 kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004; 24:1842-1847.
12. Mita S, Kobayashi N, Yoshida K, Nakano S, Matsuoka H. Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J Hypertens 2005; 23:87-96.
13. Calò L, Davis PA, Semplicini A. Control of vascular tone in the syndromes of Bartter and Gitelman. Crit Rev Clin Lab Sci 2000; 37:503-522.
14. Calò L, Davis PA, Semplicini A. Bartter's/Gitelman's syndrome: a model for the relationships between hypertension, angiotensin II, oxidative stress and remodeling. Clin Nephrol 2003; 59:393-394.
15. Calò LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC, et al. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's sydrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 2004; 89:4153-4157.
16. Calo L, Ceolotto G, Milani M, Pagnin E, van den Heuvel LP, Sartori M, et al. Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. Kidney Int 2001; 60:882-889.
17. Calò L, Davis PA, Semplicini A. Reduced content of alpha subunit of Gq protein in monocytes of Bartter and Gitelman syndromes: relationship with vascular hyporeactivity. Kidney Int 2002; 61:353-354.
18. Calo L, D'Angelo A, Cantaro S, Rizzolo M, Favaro S, Antonello A, et al. Intracellular calcium signalling and vascular reactivity in Bartter's syndrome. Nephron 1996; 72:570-573.
19. Di Virgilio F, Calò L, Cantaro S, Favaro S, Piccoli A, Borsatti A. Resting and stimulated cytosolic free calcium levels in neutrophils from patients with Bartter's syndrome. Clin Sci 1987; 72:483-488.
20. Calò LA, Pagnin E, Davis PA, Sartori M, Semplicini A. Oxidative stress-related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant 2003; 18:1518-1525.
21. Calo L, Sartore G, Bassi A, Basso C, Bertocco S, Marin R, et al. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome). J Hypertens 1998; 16:1001-1008.
22. Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC, Calò LA. Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: relationship to angiotensin II signaling. J Hypertens 2004; 22:1963-1969.
23. Calò L, Davis PA, Milani M, Cantaro S, Antonello A, Favaro S, et al. Increased endothelial nitric oxide synthase mRNA level in Bartter's and Gitelman's syndrome. Relationship to vascular reactivity. Clin Nephrol 1999; 51:12-17.
24. - and cyclic GMP levels in patients with Bartter's syndrome: relationship to vascular reactivity. Am J Kidney Dis 1996; 27:874-879.
25. Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, et al. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 2004; 279:8919-8929.